trending Market Intelligence /marketintelligence/en/news-insights/trending/f6ecX4vIEy2O1_6zTGsP-Q2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Allergan board rejects immediate separation of chairman, CEO role

StreetTalk – Episode 69: Banks left with pockets full of cash and few places to go

Street Talk – Episode 69: Banks left with pockets full of cash and few places to go

Street Talk Episode 68 - As many investors zig away from bank stocks, 2 vets in the space zag toward them

Street Talk Episode 66 - Community banks tap the debt markets while the getting is good


Allergan board rejects immediate separation of chairman, CEO role

Allergan PLC has agreed to phase in an independent chairman but only during the next CEO transition, according to the company's March 22 proxy statement.

The decision counters an investor proposal to immediately make the change, which would separate the role of CEO and board chairman, both of which are now held by Brent Saunders. Allergan's board did not signal a timeline for the next CEO transition.

In the proxy statement, Dublin-based Allergan included a nonbinding shareholder proposal to "immediately" adopt an independent board chairman, but recommended against it.

"The board firmly believes that at the present time a combined chairman/CEO role coupled with a robust lead independent director role is the best structure to position the company for success," lead independent director Chris Coughlin said in the proxy statement.

The board's decision follows repeated appeals from shareholder and activist investor Appaloosa Management LP. The firm has appealed four times for Allergan to appoint an independent chairman, most recently citing revenue losses in 2018 and "self-inflicted wounds" at the hands of executives.

Shareholders will vote on Appaloosa's proposal at the company's May 1 annual meeting, but the measure is nonbinding.

SNL Image

In response to the proxy statement, Appaloosa called the proposal "a weak attempt to placate discontent and avoid a well-deserved rebuke to management."

"Unless the board intends to make a CEO transition in the very near-term, these measures are no more than a meaningless series of gestures intended to preserve the current system of lax oversight and further entrench management," Appaloosa wrote in a March 25 press release. "The status quo is unacceptable and disruptive measures are necessary for shareholders to convince this board that it must make the decisions required to fix the company or, if they are unwilling, sell it to a more capable acquirer or merger partner."

Former Celgene Corp. CEO Bob Hugin in February joined Allergan's board, which at the same time signaled limited support for a phased-in independent chairman.

Credit Suisse analyst Vamil Divan noted the nonbinding nature of the proposal and said the phased-in approach is in line with what Allergan had previously announced when Hugin joined the board.

"We wonder if investors who have been frustrated with the team and the stock's performance will be satisfied with that as an outcome," Divan said.

Divan said the company's formation of an M&A oversight committee, also announced in the proxy statement, was positive for Allergan to overcome a "string of deals" the company has completed in the past several years that "have not created value and have led to significant pipeline disappointments."